<SEC-DOCUMENT>0001493152-25-023989.txt : 20251118
<SEC-HEADER>0001493152-25-023989.hdr.sgml : 20251118
<ACCEPTANCE-DATETIME>20251118080015
ACCESSION NUMBER:		0001493152-25-023989
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251118
FILED AS OF DATE:		20251118
DATE AS OF CHANGE:		20251118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CytoMed Therapeutics Ltd
		CENTRAL INDEX KEY:			0001873093
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41677
		FILM NUMBER:		251492877

	BUSINESS ADDRESS:	
		STREET 1:		#08-22 ONE COMMONWEALTH
		CITY:			1 COMMONWEALTH LANE
		STATE:			U0
		ZIP:			149544
		BUSINESS PHONE:		603824911

	MAIL ADDRESS:	
		STREET 1:		#08-22 ONE COMMONWEALTH
		CITY:			1 COMMONWEALTH LANE
		STATE:			U0
		ZIP:			149544

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CytoMed Therapeutics Pte. Ltd.
		DATE OF NAME CHANGE:	20210716
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the month of November 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number: 001-41677</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>CytoMed
Therapeutics Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1
Commonwealth Lane</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>#08-22</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Singapore
149544</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
of Principal Executive Office)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS FORM 6-K REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2025, CytoMed Therapeutics Limited (the &ldquo;Company&rdquo;) issued a press release announcing the completion of the acquisition
of synergistic assets of TC BioPharm Limited (&ldquo;TCBL&rdquo;) for re-purpose after enhancements to treat cancers in China and India.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">Press Release dated November 18, 2025, titled: &ldquo;CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CytoMed
    Therapeutics Limited</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    CHOO Chee Kong</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHOO Chee Kong</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 18, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Chairman</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"></P>










</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="width: 240px; height: 112px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CytoMed Therapeutics Completes Acquisition of T
Cell Technology from UK to Treat Cancers in China and India</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Singapore, Singapore &ndash; (November 18, 2025)
&ndash; </B><U>CytoMed Therapeutics Limited</U> (NASDAQ: GDTC) (&ldquo;CytoMed&rdquo; or &ldquo;Company&rdquo;), a Singapore-based clinical
stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop affordable donor-derived cell-based
immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it has completed
with full payment the acquisition of the allogeneic gamma delta T cell technology (termed &ldquo;TCB-002&rdquo;) of TC BioPharm Limited
(&ldquo;TCBL&rdquo;), a subsidiary of TC BioPharm (Holdings) PLC (OTC:TCBPY). This follows CytoMed&rsquo;s announcement on <A HREF="https://www.sec.gov/Archives/edgar/data/1873093/000149315225017923/ex99-1.htm" STYLE="-sec-extract: exhibit">October 14, 2025</A>&nbsp; regarding its proposed acquisition of potentially synergistic assets from TCBL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TCB-002 will complement CytoMed&rsquo;s strategy to
establish a next-generation non-viral allogeneic gamma delta T cell immunotherapy platform to treat cancer and autoimmune diseases. The
acquired technology for TCB-002 has previously completed a Phase I clinical trial in Europe and was granted orphan drug designation by
the U.S. Food and Drug Administration for the treatment of Acute Myeloid Leukemia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CytoMed is currently in advanced collaborative discussions
with prospective partners to further enhance and repurpose this technology for cancer treatment applications in China and India. This
prospective collaboration seeks, amongst other things, to jointly develop and commercialize a new method of manufacturing donor-derived
unmodified allogeneic gamma delta T cells. This method does not require the use of living cell. Instead, it uses cytokine that can be
manufactured in China at lower cost. Because China currently has strict rules governing the import and export of biological materials,
this non-cell-based approach can be more easily used and scaled within China. Allogeneic therapies (cells derived from non-patient donors)
have the advantage of treatment speed, accessibility and cost-effectiveness compared to autologous therapies (cells derived from the patient).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">This new initiative to establish
a China beachhead replaces the two earlier agreements with Chinese parties announced on December 5, 2023 and August 15, 2023 &nbsp;and
comes on the heel of recently announced new regulations adopted at the 68<SUP>th</SUP> Executive Meeting of the State Council in September
2025 to liberalize the clinical use of cellular products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&ldquo;State Council Decree
No. 818 released on October 10, 2025 establishes a definitive regulatory pathway from clinical research to reimbursable clinical application
for cell therapies in China. The key distinction is that these therapies are to be regulated as biotechnological medical procedures under
a &lsquo;clinical study to clinical application&rsquo; pathway within the health system, rather than following the traditional drug registration
process. This approach creates a mechanism for approved therapies to be incorporated into medical service pricing systems, providing a
tailored and timely opportunity for CytoMed to introduce its patented, off-the-shelf allogeneic gamma delta T cell platform to China.&rdquo;
stated CytoMed&rsquo;s Chairman Peter Choo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">CytoMed&rsquo;s proprietary
gamma delta T cell technology and the associated chimeric antigen receptor gamma delta T cell (CAR-&gamma;&delta; T cell) technology have
been granted a patent by the China National Intellectual Property Administration (CNIPA). The Company is currently conducting an Investigational
New Drug (IND) Phase I first-in-human clinical trial in Singapore at the National University Hospital Singapore. It is also pursuing INDs
in Malaysia which is rapidly becoming an international medical tourism hub of choice due to its affordable medical facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The completion of this acquisition
and related arrangements is not expected to have an immediate material financial impact on the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>CytoMed Therapeutics Limited (CytoMed)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Incorporated in 2018, CytoMed was spun off from the
Agency for Science, Technology and Research (A*STAR), Singapore&rsquo;s leading research and development agency in the public sector.
CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta
T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of
various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in
treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T
principle into the treatment of solid tumours. For more information, please visit <U>www.cytomed.sg</U> and follow us on Twitter (&ldquo;X&rdquo;)
<U>@CytomedSG</U>, on <U>LinkedIn</U>, and <U>Facebook</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This press release contains forward-looking statements
as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives,
goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical
facts. When the Company uses words such as &ldquo;may, &ldquo;will, &ldquo;intend,&rdquo; &ldquo;should,&rdquo; &ldquo;believe,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate&rdquo; or similar expressions that do not relate
solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance
and involve risks and uncertainties that may cause the actual results to differ materially from the Company&rsquo;s expectations discussed
in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:
the Company&rsquo;s plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company&rsquo;s
current and future pre-clinical studies and clinical trials and the Company&rsquo;s R&amp;D programs; the Company&rsquo;s estimates regarding
expenses, future revenue, capital requirements and needs for additional financing; the Company&rsquo;s ability to successfully acquire
or obtain licenses for additional product candidates on reasonable terms; the Company&rsquo;s ability to establish and maintain collaborations
and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed
by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking
statements in this press release. Additional factors are discussed in the Company&rsquo;s filings with the SEC, which are available for
review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward&ndash;looking statements to reflect events
or circumstances that arise after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>CytoMed Therapeutics Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">enquiry@cytomed.sg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Attention : Evelyn Tan, Chief
Corporate Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !U /H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBF,X4
MCH<Y[^@SZ'K[D=">:/Z_KR[]EJ&V_P#7_![+=O179&^=SXZY&/KM7%55*(1D
M*N3P5SDEL@<8..OT')R!P93(Q+,5 !Z8;<20 ".%XQCOG)XP,C/YY_M>?\%!
M?A7^S#;OH=L4\>_$^[L[F;3/!VAWT6+3R @-SK]]#'=C3;96<+L:,W#M\HBP
M<CV,@X?SOBK,\/DO#V Q&99AC)QITZ="*G0CS2Y>;$5')484U=WE.:4;.]_A
M?B9WQ%D_#F7ULTSG'/!8.A"<IIRY*E1Q5^546O;SZ)<E-KWKO1IGWU>WUMIT
M;W5[<P6UO&K-)<7#B"&-%!+/++*-BH-IRS, .QYKX<^+/_!2/]DCX237]CJG
MQ*MO%?B"RB\R7P]X%L[KQ1J#HLOV>4-/:Q0Z*EQ;39CDLYM5CO5P28%521_-
M9\>_VR_C_P#M%W=[_P )IXTU'2_"TSJT'@/PI>7>D^&5B7$Z6E\D,L5[JUU#
MOVRS7,OD.R%H[:,NP/S+I6C:EKE[!I.@:5J&KZA)*!#IFB:;=:C<R.R%H62W
M@MII(Q,A*;)&"LX\WSI#7]I\'?0VH8; K,?$OBS#9%24%5EEV5U*&"]G*2YG
M"6-QKI8:4FWS3=*=G/[6Y_)/%/TH\7B\35R_@'(X9CB5+DHSS&E5Q-&22MS2
MI48.=%2:;7ME!.+YE=']"OB;_@MC\/[359H?"7P7\9Z]I,:!H-4U+7]$\-W,
MLP& DVDM::K)$@RX+M?3= ?+QTXL?\%NF:[+O\!;I;,8.S_A,;9[H')&&==.
M2#)7CB X/;%?F1X._82_:P\<_P!DSZ9\&_$UEI^JK*]MJVO1#1K*%(SM7[89
MMT\,CMD*KPHNT$AR" ?8S_P2M_:V$1+:-X(60J6\@>,K9I@<'Y"BVI82$=%=
M5!/&_/3Z^IX7?1&R.#PF8<2Y=BL144:<94^,L3F%9SO&#:P]/#RI3G>\IQ]I
M"%/WYI\M)7^07B-](_,/]IAEM3!486E*%7+*^'IM-Z).LH+D?-%1>MX\EGJF
M_P!$?"?_  6T^&EYJ?V;QK\(/&WA;2C"SG5--U;2?%$HFX C738+?29MI[,;
MI<=&P.1]S?"#_@H-^RQ\9'L;#PW\4-,T?7+V"TD'ASQ?;W?A75([B[N!;BV:
M75%.EWU[+)^ZBM-.U2]993Y0=R0Q_F1\:?L4_M3>!;+4K[7O@UXM.EZ5/Y,^
MI:58'5K:9,G$]L+;_2)(<X&\0;6SE6)R*^9+_3+[3[R33=7T^[TS4; F*6QO
M;.[L[J,HY),L5TL4D#P3JS.5+%'5@%4C@Q'T7_!'C+!U9\!<8K"8SGG2Y89I
M@L72E55-3I0K4'5=;DYI*7/%J$[\L7SQDCIPWCUXO<,XA2XHX>CB,'2</;5I
MX'$THTH.7ORCB^3ZM1<X:*5:I&,K6BVTS^]VVN[>Z2.2VN8KB&1<QR0.LD;!
M@K*5F3,1+*P95W_.N70$*2MH.X(V ,. 20%*D]BIP1P0>@R#Z8K^-?\ 9Z_;
MQ_:'_9WN["TT;Q1J7C'P9$5#^!O&%[?:E8I;1C;(ND7=W-(VC[ACR4L MJH)
MWV<S[)X?Z1_V4OVY?A+^U1I'E>';H^&O&VG?9K?6?!&MW]N-3BN)+>.1YM)=
MQ"VKZ<&,H6XCAB=3#.CP#R@S_P I>*7T?^._#&^-QN'>;9'S\L<VRZ#EA_9Q
MO>-?#MRQ-"5-)*5:5/V%24DX3:BY']'>'?C=PEQ]*.$IUHY=FLD^7!XRHIU)
M5'9.5/$0B\,Z4Y.]*/ME)0336J1]R#H..2>GN3T]."<9Z=^E2(K!LD$#:1R1
MU)'H3Z54BD8K&=HQA3]XY.,'=RJD9QGE0><D#D"RTX&,;<GKN?:!UX!VG)..
M.F:_$.>"T36DXTK?RSDKQC+^71;RLE:S:9^SQDI)ZZ15Y2?NPZ)M3=H--[-2
M:=U9M--ST57-P!V4_1^YQ@?=[@C!^HIWG +D[0>.-WK[[>WTHYX:>_!INR:E
M%QOV<DW%/R;3\BM5=\LM.T6[]?=M\6FONWTUV)J*C$JD D@ CUS_ $'O^7-.
M#*1D$8Z=?\^M--2O9WL[76UU;9[-:[IM;ZZ,/O\ 1IIKU3U3\GJ.HJ$S$$@*
M"0Q7[V,@=6Z?I^M E!/ !Y(^]Z#TQSSQ1=<RC=<TDY*-];+=M;I=KVOTN"U<
MDD_=M=V=O>U5I6L_.S=MG9DU%1^9[?K_ /6I/-Z\ $=BW;UZ<<4Y/EBY/9;\
MOO/=+2,;R>_1/\&-JUK]79=KVOJ]DO-M*^FY+14'G>H ]B__ -;G/MZCUIXD
M!SC!P/7N>W0^_P"5&FNJTWU5UMNKW6ZW2%K=JTM-6^5V?^%VM)^46R2BH1*2
M<;5!SC!?GV_A[\?_ *Z<) 2  "3VW?\ UJ3DDD[IW:2Y7S:MV5^6]EKJWHEJ
MVD).]M&KI-732L]5JTK/RW6UKDE%-+$=5 ^K"DWGT'_?0JK>GWE6]/O'T4T$
M]UP/7(IADP>@QZEL?IC^M+2]FTO5I+[W97\M_(ENW=_X4Y??RIV7F]"6BD!!
MY!S2T)W5^_R_!C(I3]U<\'.1ZX*D?Y]*J2J"000-N<J, L254 <8&"1DGIE0
M.32EE"QG/\ '7NQP0/KGD \\=Z^+/VYOVH-,_9B^#&I>*89+:X\9^(P^@>"-
M,DN;>":36KBU+#4VMYW6>6TTI'2XN5A1W61H$*[F6O3R7*,?Q!F^"R/*:$L7
MF./Q-+"4Z,(RE9UFXU)2<4VHTZ/M*DI65HQ;;6C?CY]F^!R'*L=FV9U(T,%@
M>>4ZDIJ+<J2YJ-D[:U*ZITU&]_>OJKH^2?\ @HO_ ,% /^%,6M[\%?@_?I)\
M4=6LE_M_Q$0LUKX)TZ<J7-KB-A-XBO83''"DT<EG8VLHN71;A=R?S67EUK'B
M+59KF\GO=<UW7M0!FEN?.U._U+5-0N$7>8\O->74LQ7RHD(9Y,1Q!=V*FUW7
M==\4ZWJ/B+Q+J=SK>O:_J#WVI7UY*3>:CJ&H2G+[7*R.UU,Q6&-%).!$N",5
M^KWPD^'7@/\ 8<^'GAWX\_%G2K?QC^T;\0=%%S\'_AA<!Y-.^'VD:C;PW*^*
M_$?EQ!(]62ROM/M;R:[6*97C;3=(%PLM[<6O^E6"P? _T3^ L/B:^'PV9<:Y
MAAH5</0G&G#%8O&3HQE-N<UBG@J& ^L*7OQ:G!J,5[6;Y_\ .;B3BC/_ !EX
MCS#,<QS19-P?D_UBMBL3B*KP^5X3+,,Y>VJ5L1S485,16C2C'#X=0=3$3YDI
M)09PGPF_80T#POX4LOC#^V=XO/PG\"W$27FB?#JRNXYO'_B&#>T=J-4AM8KF
M2'[9*/,BM-.MFDA@G$-[+:21/.?2-0_;>\(?"RQE\*?LD_!;PU\-='1#;+XK
M\064&J^*KZ*-/*M;XQ-<W+0S2#,WE7]W< E\2\YQ\3?$SXH^/_C%XLNO&OQ'
MUV\\1:_=IY<32;8-/T:S61BNF:+8+(Z6.GAB9DBC=RSL[R;78UY_L;G)WL<8
MQC &>AY_//<]3UK^(..?%;CGQ!QU;%<0YUBJF#KS]I'*J5>O3P-&E)?NJ<*5
M.I3BY1I\L95)QDY-.:C!R9^4YSXNQRE2RKPVRO 9/ER?(^(,5A8XG-<QI+;&
M\[A2="AB)*57"QYY<N'E!>TG\1]$>)_VN?VDO%EZ][JOQ;\5+]IB2VF@TR=-
M&TYXT!&R.ULX3!YF5(/EM&QSS(,8KRI/B5\1(;PZA%XZ\7K>M-YS7":]J+N[
MAM^75KAE^\-P!4J#CC' XT@CD@JH!)(/0=.5P>>.@]SS2*^-Y1@&5=P).TL5
MYV<[?OC*CJ!TXYQ^<RI4ZS=.I#%8CE<)5*=/#X>I54(3A/W:F'PZKIKDYKQJ
M*5HMMM<W-^95N,^*\555;$\1<1PJ*?/[7"YUF,7%W<FU2J5ZU*2>JY9PE%1E
MHERQ:]O\(?MU?M&>#];N7TOXK^)KHJHTKR-;GM]:L$!9)=CV&H1/#%M5,),C
M)+C<%=1FOK"U_;%^$/QSM8O#O[6OP3T#Q)9740MO^%B^#+)M-U^TDD"1K?2+
M:W"3W!#,UU<-!<1[79C%@[:_.^6'0]:T^VT7Q'#Y5I9P72Z5KNF6\;:MI<MV
MJO;I=V\@:S\1:9;7JBXFTK4%7RLBYL)X[A-C^>S66M^!KJQM]3V7.E:E8QZA
M97FFW?\ :-M=6EU,8 D)6:2>#4[5P4DT^Y=-2C"B62#RF$S?TOD_"'"/'.4X
M+'>%&>X_A[Q"RS+7+%Y)5S"MAZF9XK#14HSHUI5J'[RO6I3@\.J%24%RRE*H
MI**_2<E\2>,\+AJ5;!Y[6S[FC[*KD?$O)F.78JE"TJBQ-&:I\S46^1KE<9^]
M=['W1\;/V#Q:^%KCXP?LK>)?^%S_  DD<3W&E6)63Q_X6@FCEN1%=Z?M@-VB
M&-E>-[&RNEC0.8I 3+7Y]>'/$7B+PGK=AXJ\+:K?:!XET6Z>73=4TZ22SO+&
M[MIE0+,GG1S\R0SQ2Q2J\6[S%VG)!^I/@E\>OB!\$?$<'C#X::\+%II;.35M
M$GDDGT/Q##8L/,T[5;"Y#2#[1$6C-U;J)K*?;+&Y8")_I?\ :#^"_P /_P!I
M_P"'.N_M;_L[V<&B>+M"C%W\?_@G:1Q?:;2Y,;O>^,-!LFS+-;2L3J%Q8VRO
M8:U"LDJF+5+>^ME_4O"3Z0N,6,EX8^,E&=?"8_\ X2)XO.*,88C#XZ#6'KX:
MK&M2;G2IU%&%#'1E3A7513E"G=2E]9@:F2\94,5GG!$/["XXRC_;,SX=PU25
M#"XG!85WS3'996_=*G#"/FE3R]4:U2HERPK6BVOU0_X)]?M[:=^TKHT7P]\>
MO#I'QC\,Z9;1W11/)L?'-A9Q^0_B#2@/W46HX@*Z]IH6)5OI9+K3(EL#&L?Z
M<7=U;6MM)<SLL<%NDMQ/-*V(X888W>263./DC'SG:=P X&W)K^$_P'X\\4_#
M;Q=X8^(G@75)M*\2^&M3M-5TNYLYVE9W>>-UTX;56*:TOV@\B> #S;B!VCBB
M9I$5OZ//VJ_VC_%WC?\ X)P2?%*QT?Q%X!\0^.H?#WA[5M.U/37L=6@2_NI+
M'5WL8+V.*5=/U06HELY6C1S;3RG##+-^6>-_@)0X:X]X<H\+U,-3R+C_ #;!
MT\'1G6I*M@5B\0WS4Z2K2=>C+#5I5\/K122C14E"5-K^N?"3QJEFW!&??VO&
MO7S+A;#3J3GB<+5A3QU&C3IPHQGS1TDY?5_:>_4E=2D]5)&!\?\ _@L%\/?A
MYXLNO!_PG\'7/Q,N-/N;C3[[Q!/J']CZ'<:C&HB@M]"86]S<:N\MTLD+_9XB
M=\;QH"RUP?P[_P""T>@S^(TT;XN_"K4/"VD"&-;_ %K1+NYU6[TR[F*.CWFA
M7$%IJ26OE%W&R,S2%554+L!78?\ !*#]F3X8)\&XOC7KVA:/XE\;^)-:U+3;
M:YU&WL-8MO#VEZ->&PAT[2HI%,%G/.8Y9[AGC\]9YFRNW9N_0+XW_L??L_\
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MJ8B52NL%6RW#4'AI4:E6KB5.G3KNO*G45*K.+C'E<OS^7BUF,O$/AO O"8_
M\*XWAS'YMB:=:ASMTYTY8FCF4ZSA3<:5*C*$W1<5)<RBI:'])PRW0D]^$#9_
M[Y0]/PZ]^U620*22QX8*6X4C@$G!VC'/H!],U_,1X:\2?\% _P#@H=KOBOQ?
M\/?%D_@GP/H=_;R:?I:^(KSPQX4L;B%C=:/I$!L+2XU#6O$<<!CO;_4)X5ME
M<QP/)& BM] ?L8_MF?M _#O]H6?]E?\ :GN[_5+_ %K5I-!TK5O$AFF\4:/X
MH1&%E91ZE;PRIKVD>)XFC?2')CCLUB/E333/+%%Y.;>!>>97@\[J4\]X?S'/
M^$<!_:G$W#.%QL5F.3X.K@UB%B*G-4<<52HT*BEB'3IP5.HXTU:4DY?497XT
MY/C\QR^AB<ESC 9-F^(Q6"R[.\70E#+LRQ%*%3V.&P]3V4;5J]6,>1*4K14I
M/F46?=G[<?[=<7['[^!K2U\'6?C?5/&!U9Y-/FU=],EL+'3HXS%?[8K6Y,JS
M3.(0C$ ,W&, CZM^ _QCTCXW?!WP'\6]+1;2T\8>';'6+FPC8RC2]46$1ZSH
MHF>$-.=-U6WOM/EF*J^8L@YV[?YY?^"M/B._^(?[6?A/X>:%I5U<ZQX<\'^%
M_#EE%9W(6ZU34O%;OKEBEM&Y1%=1?/;*\SQVV\8FFC4G;U/[$?[7=M\)_P!B
M_P#::\)ZK?VRZ_\ #:*XU;X>VEWJ=S;7>JR^-(O[#L=/TA887^PV.C^)+;38
M[.]MWFC74-7>:X:&VAEF'V./\$,/B_!KP^XER3#_ %CC'.L;EE7.</1JNO+$
MY;G>:1RW"5YT8.3PM.C5JX=^T=.4:BKI2G!TY,^.P_B]F.#\3.+LBS/%TWPO
MEF KRRFNX1I1HXO#X+ZVX2J2NL15G6J?4_8JI&2E151*2JJG'[R^'G_!3S3/
M'O[5<_[/=OX'L+;PP_BS7O"VE_$ ^()2VI2:';R*;J/2C9HL/FZE#=V)1YW3
M?:O)@*X1/UC&8V5ER&!8#OG@\X]E_P#U<"OX?/@]JFH_#CXM?!;XE:]:7DUC
M+XTTGQ!:71N5>;Q ;3Q"MGJ4KLLDTIN9-16=KV>Z6&2XNFFN&15E;']%O_!2
M7]M3Q)^SEX.\/^"?AH8(/B1\2=(N+ZQUV[=T'A7P^DDEL^MVOFHMI<ZG-=0O
M#YEW<6XTZ)Y-0*,+509\6? O^R>-^!>%. ,/"O7XBRNEAZ]2=9U</4Q^ A1H
MYY6=2+JNFL/6CB)U:<.;V7LW""OH7X<^,U3,>#^,.(^+\1.-+),VE/#THTHT
MZ[P^,Q%6>78>,)NFDIQ=&E"I-QIS34FXQN?J^)&<9VMQ_$58*<\<';@].P Y
M'4DX-X]OS/\ \37\DFIZW^UEX.T2Z^.5O^VO\-=5\3KIEEJNL>%M)_:)\.>)
M?'!M(IK"X;2KO08;J2PUB>RA6VMM1T:UN'.(EBMWD9\#]>?V;/\ @H5;>/OV
M2/'_ ,:_B1IEK%XN^#37MAXNM[9HM.TWQ%J3V]M=>';O3D@%TUJFLG4M/M;H
M-:"&VU0W,8D>")I!\'Q)X+Y[DN4X;.LIS;*>+<"\SPN19G_8E'-Z.(R?.\=B
M'A<)@<51S7+< JM.KB%*E+%X:=:C"?(O>4XGV/#WC%DF<8_%9?F.#QV02HX.
M>8X:MBZF$Q5'&8&G351U(?5J[G2JR4H*-&49)\S?M$XI2_5UYW\IV!9@J,?E
M7DD#(&0C8R<#.#UX!K\O_&/[?WB'PS^VMI?[+$?@'3+W0]0UG1](7Q4VI30Z
MD)-8T)]4\Y+78866VN(GB8",Y"$$$<C\L?AQ)_P4*_;O\1^)_B7X$^(&J^$M
M \/ZTU[IL<WB;5O#/A#2;V] FAT+PG!86EU+J%YI]FI2YNYHFMXWEC>28.VT
M^7_!N\^+]Q_P4.^%MG\>%U#_ (6AHOCKP[HGB";4Q&UW=1:;:O;V-T]Y&H75
M8YK7RY(M3!/FQL(V12A%?I'#G@3EN68CC3#<3<0<-YUG'#G!.;YICN&\NQ[E
MC\DSC"8.&-H0K5(SE#$2A2K0C7A",'3JP<'%;KX7B#QGS3&+AK^PLESG)\'F
MO$4<'_;.,PCJ8+&X"EB/J]2,&H4E!591<HSYYJ*E:\FF?USV_$8&XM@GYB5)
M;H23L55!))X  [C P!/4%O\ ZL'H"<@>@(!_SZ]>]3U_*4;\JNVWJVW'E>KD
M]8ZV:32:[Q\S^H(VY8VLURQ=UL[QB[KR;;:]3(F $*AF"KLV,Q.TKN8+D=2'
M .4'!9]JC&[(_DB_X*7?M S_ !L_:1\0Z-IFHO/X-^%DU]X*T&"*7?;S:];@
M1^(]4A-LCI.3JGF6;/,B^3]D6-7<A@G]0/[1'C__ (5=\$/BM\0@LKMX0\!^
M)-<A2!A'.]Q9:9/);)"_:5YS&L74^85 SG%?P]7FH7-]<7.JZA)<WEUJ5S=7
M]\R%)+F_EOM0ENKHB. !H[F_9[BXN/*"M%))OC*,[$_VC]#'@O"YIQ%Q'QQF
M5&'L.&Z'L\/SMM0QU2G*=>K!+25\)#V:4KQBJC<4I.[_ )$^E3Q97P.7Y-PQ
MA*DE/-\3#'8RG'15<O=6G3:;>L?9S?MG*%F_9V;:;1^@G[!'PB\-:IXC\7_M
M$_%&V@F^%OP"LVUDV=R%=-<\9W$:Q:#I$<,T(@NC;S3QW,4,A"_;FWNNU@%\
MU^,GQ9\5_&WX@^(/B'XLO)II=7OIX]&TZ1!'#H/AV.[NI=*T&UAC$92'3K22
MUMA/)N,K0/(Z;I!L^J_C0$^!G[(7P ^ %@88-6^(%@/BQ\1/*V6[3O?R33Z=
M:7UI@S(Z2M;,I)&3&C( A4U\!!G8AF8L6!!+$LW"M@;CS@8'R]B/:OQ_QMX[
MQ'B%XA\0YE4K3K9?@L?7RS+H2?[JE2PD_9R4(+W%*3ASRDHJ3C[--NQ_&WBE
MB8Y)E^5>'6"JMX7+<'A<1Q.Z?NTLWSG%J.84OK,4UST<-@L3AH+"W^K2<ISE
M2<ZDFY3RX([=>G8#U]CUR3Z# %*0<=A@8R#GC\<?7.<\4#[Q_'^24XX[]^*_
M*.F_3\$OT738_#;MJ:?PSM%QZ0A%*,*=*.U*G3A[E.G3480@E&*216=BRNJ_
M*QZLYX'OP.1P0 .I(Q6)J.A:]K/FW&C7-M*]BB3_ -EI<"#4[Q P25K.WD15
MNQ I\Z>,S0F.!'="[ 1M8U*^>TLKJ>&'S)(L[6RY5?E.20IR0,9&!G(]3FO0
M_@7^SOXF_:$L_%^N0?$;P'X&TKP0+*?7-2\<:K+8R112*MQ+/;6]O+%=M;+"
M3Y+J0'E C9FW!3_17@=PRZ%/,_$//,=DN7\/Y'C(X'&4<72IXU3JU82H2=L1
M2K-N4,3RQ@E:,Y*22<(M?8\&9!C\]S*"PT</44&U"GB:^'PF'E^ZJ*7M<5B%
M[&E%14I*573FC&*7/*)Y!I/B9#_HVILL,D99%EB0R12E&*;0<1$[64@OCD@J
M5P@+3:EK.B36KPNP>-W:-2()I!'<S9CGN(H'C,4<S+B*:2-7WQ)E0C$,?MN\
M_97_ &1/#%QH:^+_ -L>ZU8W1BDU*T\(>"+G6X I4/-&=1BM5ETU9-Q6WN+B
M2X=\ F$8R=+1M!_X)OZ/X_CT#3H/CK\47GM;Z"SBU.ZLM,T*_N1$ZQ6(=;*S
MU%+BXD CMV8A)/,3*DY!_1+>"%;BU\5\#UN,\1C\G5/-,3A^',ME+"0J8>I*
MIB95:\YTY4J%=PE34=(JTK0221^B0\)VL5*<^)>'<KJ2ESU:?^L.#QU6G&+Y
MI^PHX&2M*UU+VJ<)1Y8PCS)GA'[,GPMU/XPZ%\<M(LXKTM\/_ <OC[1KHK%;
M6-IK6EW-U#J-C*[;1;IJ5I$T\,<DDGERW$(,3B,END_9V^.7B'X"_$W1_&FF
M-->>'[Z6VTGX@>&9#;R6'BGPM=/';W]K=VQ62+[1:V]S)=6%S(LJPR32AHG#
MC'M'C;]KO3[?X>Z[\&O@;\)O#?P;\%:U&^F^(+B"X>Z\4ZJ(7PT-[J C1#.N
MS%Q/.S*YD9&;:Y!^(BHVK&1]R)(-SX,X5$2-4EEX\Q@L:G*Y4C"G)W&OYU\3
MN-,!Q]Q;C^(\ORVOE<.>E[.CBDXXM>PISHRQ-1VBXSQ4DZKY7IRWYF]O)XCS
M?(>%,\X8QO!>95,7F^1U^;-L7.*P>7XSGE&53#U9TN58BC'D<:T*JE3JN7O1
M:>O]+?P$_8'_ &5=)\577Q_\/Z!#XU_X3R^_X3WP':>( E]X;\$Z?XD6#6[>
MR\/:%YJV<-O:S.&M4N;>3^R T&GVT<?V0R-[Y^U]\ I?VA/V?O&/PMTV>#3=
M5O;:TO?#\Y9K2TAU717>YT^&<V\4A@M&(-OBWB!5G3)QD'Y!_P""4'Q=N?%G
MPG\0_"_4KDM>_#?4X9-*$LP>9_#.N/>3V\42$%_LUG?6EW$<,<?;(4.!%&*_
M6=V#+'@?,K9&XL,':4W+T^8[CCO\Q(Z<?&8SBOB2>>97G6(S;'9EF&2/!5\J
M>/QE?$0PWU*>'G0A1A5JSITXQC05/W81<HVA*34VS_3GP]H\)\:^&6#QN7Y?
MA<'A.(\%46;++L/2]K5Q]2G".+=.I&'M.2GBW7E0IJ:IQI1ARP48QO\ R\?L
MH?MU>-/V$)M=^ GQQ\ :W?\ AW3=4OKVUTS3EM-.\1^'KZ>\@6^:SBOS8PZM
MI-W*S:E!/]H:<-/,K.5"11>]?&;_ (+&:QXJ6R\-?LS?#W68M?N=5M#_ &QX
MKMM/UB;5K.&2-FM=!\-Z7?:@9+C4;E;K3+FZNY+*2R-N]VIDE>-$_;7XA?!'
MX0_%.2S?XA_#WPMXMGL-TME<:SI<%W<022M&)'$KKN9R84^=RS +P<$UD>!O
MV;_@A\-=4_M_P-\,/!_A[63!Y)U.QTNW6\\H3&Z$<<L@=H]LQ,B&/:48D(P&
M:_5L=XI>%>?9G4XISKPSS.OQ5B</B)9AAECL30R/,,UG1O/,9X>$E!.I5C&;
MIPIJF[)*G.:O+Y[#>'7B-E6&APUE/'6%I<,TZBEAL16P^&CF>#POMW56#@_9
M\TI1;>LY<SUC=1=CS'Q]X*O_ -J/]DS5_"WQ'\(/X2\2_$#P&M_<^';UUFO?
M#OB:...^TV61K>:$B0:I;V\T2!T81EXI@"IW?R^_ 7X/^._CG\:O ?[-&L7V
MIS^'?"_C#7E\0Z)O4:5H-OIVHQCQ;=%(E7;<:T;40RWDFX%)WCC0*2&_J\_:
M=\0>/_"OP1^(6J?"WPQJ/C'QVOA^>P\-Z%I"12Z@^I:M(FFPW<4<TL*.;)[I
M;IBTA(\H @J#C\^/^"67[*WC?X3Z?XZ^+7Q>\/:AX>^(?C;4+C1;73==%M)J
MEOI,=[-=75]/,+B[D,NJ7HDF>1G#E#M \O:*]?PI\2%P5X=>)F:2GD;JYEC<
M)5X0X=<EC\=@,SQ6%QN78C,<##$^UG0AEF"QKBXTW3C6JPC4J.52E":\[Q!X
M'J\4\<>'.7_5\QJT,#AL1'B/'_5X4/[7PN'G1Q"6)G2C'GHRKT5.$;N#4I0Y
M7&4T_JW]N;2[#P[^Q'\;M,TVWM[72-(^&[6EG:P+&MM;Z?:7VE01Q1[4BCB,
M:*B1[0=Q&>#P?S9_8/\ A;=?&W_@G3^T!\.-'(_M/Q%XI\20:.6F>V@EUFPL
M].OM&26Z6.4"WDU/3;=;M51\PNT;95C7[Q>)/"V@^,O#NI>&/%&DV.M:!K%H
MUGJ^CZG#'=65]:R&-W@NH7RDT9:-'VG@,FY0#TQO 7PV\"_#'1O[ ^'_ (8T
M7PAHDE[+J#:;H5C#86CWTJA9;DP0@1^8X"AB5SU/T_+LC\0<3DG F8\+X3#U
M<9CL1Q;DW%6&S.O7<U4J9-5A5A0KJ:DJDIN,_:3E[]23DYR;;D?>YYX?+-^,
ML%GU3$_4\DH<+YAP_6PT:<8WECZ+HT'3IJ*5-4H.$53BE"+CRI)1BE_.'^Q'
M^W98_L6Z/XX^"'QW\$>(;<Z;XEU#4U73+2SAU31/$HL+:SU#2=1BO[RQ>\@N
MOL5M-87UJTELD,Q91QM,WP$_X2K]N3_@H#;_ !^T3PQ>>%_!WA;7=*\8ZC/>
MR2W+6FG>'X5MM/TUKV,-:#5=62(/.EG<'[(A22V,+R2JO]!/CS]GCX*?$K58
M->\=_#3PCXLUFWMELH]4U?2[6:\6V4G9 ]PP621$#G;O+%02%( X[GP3\/O!
M_P /=%@T'P5X=T;PMHT+[XM,T6T@M+-6W,S%DA"B4DLQ8N6;).21@#[W&^,W
M#$?];L^R+@_&87CCCC)HY#FV:UL1+%Y7#!8JA3PN<U(T,1ST\16Q=&E*E3>(
MIMX=257#^SQ%*%27QN7>$W$L:^0Y1F_$N QG!?#.:5,SR7+XTZ:Q]"<?;3P;
MKSC%5)PI8FK"4IU*DY2C?#RYJ%24#^=?P?\ :OCA_P %?-2OD,'BC1?"7BG7
MM4ED46\]M:>'?"7AJ32-+,:;!]I31M8O].@1R(FCNX48>8Q"#XD_;"^$>K_!
MK]J#XJ_"G289K#0_&OB2SU;PIHEHJ6%GJF@^+-;N-5\/Z/9VZ3M/<Z=I&L"X
MT[3P[J!>:=)>;0DGV:+^M3PK\!/@_P"!?&%]X^\(_#KPIX<\9ZK!?6U_XCTO
M3(+;4[NWU*2PNK^.>XC!+K=W.F65S*#RTT)ESNDD+S>*_@5\(?''BC3O&WC'
MX>^%_$/BW2H+&UTSQ#J>F07.K64&ESS76GQ07C@RQK9W-S//;[6'E2SS./FD
M<GULA^D6N'<_P6/P.2^TRC#<!91PE++7*$Z:Q.38OZ_EF<15G3HU89GA\-6J
M>RA#ZPL-*G6<J=6I"7#F_@2\ZR;$X&KFT5F]7BVMGSS&$73FZ%:M0K8K#R4'
M%5*$J4+1H2YJ4.9\D(\S/YZ_^"C?P&3X$?L__LA+I.DPP:AX1TG4M*\0:Y):
MI;S7.N7.G1:S##>-&WD"Z34A<#S,L9FS*V&#!NK_ ."E/@/QO\4/A+^S;^T/
M812>)=!L_A[HWA_Q9<:;9FZDM;S4I/MK:M<0I!);Q6-Q+>R6<3,=L5Y'%)(R
MH0R_T >/OAC\/OBII,&A?$7PGH/C/1K:_6^M]-U^QBO[*+4%#A)X[>8,BRA9
M'&\ =3DX.*U[#PIX4T?PW!X1TO0]*L_#%G:C3+;P]#:Q)I-O8JS.+&.T8&W%
MLHDD B9"FTA-H  KP\L\>\PRK_4/%/ 2Q.<\'9MQ;C98Z>+=.MFN&XIQF(Q.
M:48XBJY/"2P2Q=14:T4HX9TX2A&/+!+V<U\$L#F2XJPM/,</ALIXDRS)<'0P
MSHP6&GBLEP].E2Q%2G'E@HSJ45.LHV56,I<][MO^1B\UK_@G1!\.K;6]/\+?
M'_4/BC/:1M<>%I_%&A6&F1Z@EQ!%J%\/$']GR6S:>\LDC0VEJ)[@82&:"/9$
M[?J9\*_V4OAM\1?V#?B[)\#/#/Q0\&7OQOT6&^B\._%+5XM3U!]5\%:M;:K9
MC2A:@V1T[6KG3#%970AA:[@GC,T,;*\8_3*#]D3]FFUU:#6H/@S\/X+^*]BU
M2*=/#UFK)?6\YN(9U 40AH[B1Y%&S8"V2N,8^@X8(;>)(K9(HX(0(EA@P(DA
MQA$1$PH1,DQJH58V)PH.16W&?CG4S2EEBX<J<8/$8?.\OS^I2XJXHI9A@9XK
M+\7#'QP&!RVC0I4,7AI8BG&K1JXE5)P5!0E*:JRMAPGX,U,%6QD,[>1I5LJQ
M&3X66 P=*GBI0G""I8E5X-5::C&BTXP:C.4HMZQ5_P"9[]AK]OGPQ^R)X,\6
M?!SXO>#_ !/;3V'B75-;MI-+M3)<6VLW-H\6KZ#J5G>R6\EM(;J*%K:XMQ+;
M11M(,*0&'D_PV^.!_:$_X*1_#GXLRZ5_PCX\3^/=$&GZ-<RQ27EOIVE:7+%:
M)<-#-.F9K>U,SO&ORR2'?&HP3_2MXT_9I^!/Q&UM_$7C?X4^"O$NOF-(AJ^K
M:-:W-^45Q*JF8H"Y+HKLS9=F5222!B[I_P"SU\%=&\5Z;XVTWX6^"K+Q9I$:
M0Z7XAMM'LK;4["..W-JJVDL$:"%EMV9 P0/U+,37H1\:N \-C>,>(L!P'F>'
MXHXYR7,L!FN*>.KUJ5'%9SAY0S3%4J%27)R8G$RE5BY+FH0C"CAXTZ48P7FP
M\(^,JV&X=R6MQ?AZG#O#.92QV%H8FA0C-0AC*E58&55056NHIN2J5JDZD54<
M+\D8I>YVYS&",;228R.\?&T_4_\ UZGJC"VR/"$  G((!^; S@YYS_GFKU?S
M9'6*=YROJG45IM-MKF5E:5FD].BZMG])0;<(-\B?+%/V;O"ZC&/N/K'W=/)G
MYJ_\%5-6O=,_8G^)WV*[DLY+W4? &DRO$<22V5[\0/#=OJ5KP1E+W3GN+67)
M \F60@9QG^5WP#X<G\5>.O!/A.TFCAN=?\6>'=(M6,8>.*2?4+6".8'*'R(H
MPMN0<.\DS$C;\U?U%?\ !6JVDD_8N\93*Q\NS\2?#R20J3SN\<Z#;*&'NTZD
M$]&7-?S1? >:&V^.?P?N[F6.&"W^(GA.2:25MBI&NLVKLS,>P\H*2< %E)XX
MK_1?Z*Z^J^"OB3BZ*YZ\JF?\T4ES)1R7$W?1MJ%Y+6ZLN7WK7_@WZ1%18CQ>
MX4PM9\N':RB5.;ORO#U<?1A4GMI%1E)\K5]'[KO8^Y/^"A6LRZA^TOKVAFWA
MA@\#>%_"WA&T:(8:2"#3X[J1P@P(PLDK *,X"@ G KXJ13E<J>.I(&/NGOD]
M\8KZ^_;W8-^UI\63D*KW>B,H))8J^C0E#MXW*[$*&^G8@5\AB3@87. .A'''
MX5_ =2M*K*,ZBM.<:DVFM7S8BNFW;9MQ>C=[=S^./%"I4J^(7&,I\R]AGF(P
M=!MO][@\/"FL/63O9J?-**VE:%VDN4EX![9_SG_Z_P"'I29!Y';J<< 'USCK
MCC').,9Z&(R!C]TCMSGOC/3V_GGM2F3<C1LHVDYX(W#)SR<'UP .3U'K54J7
MM:E%3A5=";DJTXT:LU!)M;0IR;327PIM=3X*/ORY(*<I=?<DE_X$XJ+TW][3
M9G.ZEK>GV?FV\S-<;TD+ID*GE+R[[VPGEJI^>0MM4_+D&N/LC(L.K:IH-^;<
M69AENM+MYR]W/8AQ(+U8(]WVNRLF*SWP&];:T$DTH2)6:NV\#:SX2\#_ !)T
MK6_B+X"LOB/X-66\?4?"EU<WM@-1BG">5=V%_ID\%S;7MJR%3;AS;3AG9XF/
M!^YY_P!M_P"RC39OA-^SS^SM\/;"RA>UCEF\"P^+-9N;0J(C;W&JK)H$]G<2
M0$QS":*\F*EV,LP;;7]MT,=PYX(\(Y;6R[@_,^,<!Q7ERJ9UGM9QGD4L54C#
MVN"Q/(J]2A.G2E*-.I6H4*2Q'U=*NY)P?Z_PMDO"M/*:N8YIQ'F&!=:$E+!_
M5\56G6:3?+#ZO1J15I)/WI1^'M=GY_Z'+XS\7ZE9>'/!_AVYUG6]0RNGZ+X=
MTF;4-3U!US*7LK.!6EO-X<3 VZN-LBX"YQ7WE^S#^P[^T'JWQ%\(_%7XG^&;
MKX3?#SP9KUIXJU_6_B&G]C:@]MX?EAU.6TA\-WD<.IVXG@MRD=Y<RFR#-EXU
M564?''C749]1\3/\0?#.FZ7X"\12WS:S<0^!8[C0M(M-8BF,PU/PY82W-_<^
M'R2VZ\M+/4/LEVZB001%W![MO'7Q8^+?A'6_$'BCQOXU\;V7AG5;"77;;5M7
MU6_TO31J BBTO6(]'NYKG2]/$UXQC-Q:6UK-$P,T5Q& K*^,>(\-E?AI5XQ\
M&^%,@RCA_-,#3RO/XX[#XR7$^'Q&*G+ZU*=65"&$J8*$ZM66%]C.M-5$Y.$8
MM)^APKC.!LKJ5\[K99Q!GE;!3K5,%A\#5PZ5?$TE*5!XNC4JPQ/L'.WO*DHT
MWSNK*$?>-WXXZUX7\2?&?XHZ]X,#'PQJ_C36K[26*".*6WN+N;S)[:-04%K=
M20I/",JVPKE!R:\RC (.1T;C_OE>/I[560;(P5W;?E3R@ J1JJGRPH& " 2"
M><YZYZV83N5CC'S=./1?2OX@E?FDW.I-N3DY58N,O?;FU%249*G%SDJ?,D^7
M6Q^/YKCZF:YGF&95J*PU3'8W$8J>%47'ZJZM1M8>5XJ,IT8J,)5*3G2F]:=2
M:3:_2;_@EQXBU;3_ (_>(O"^E-#"_C'P!J]K]K=6E6SNM.F%]:W#0[HFD$4]
MLA:,2(6#LBR1[BU?3'[3.D_MC?LY^%K3QG>?M2W_ (EMM8\4Z?X?ATRW\)G2
M7@&L/(8V$HUR;[9%:I$J!'V&7'F$!EKY*_X)>2A?VK](4<L?"?B<C(P&6- L
MA3KNPT^UN05*8YXQ^FW_  5(+#X*^"D!P!\4/"QR><[1='KGOO&,G "X/M@Y
M)>ZWO>VK3OS*RTT:TTOUUNK']W^$V#EB_H\8K,:&/S;#8[(,3C\%@G3QE3!*
M*QM57<:U%MTX-XV5.%51DX*4/AO)QZ[X=?#/]I_X?V&M?$'Q]^TD?B-HEM\.
M_$&I6?AN7PN=,CL]4?2$U+3;Y[U=0NY'.G;6.0OS,A(C#$L?,/V:_P!OKX6:
M5\'_ (<P_'WXMZ?)\2?$%[K=O="6*>_OH+>W\37NG6<WB(:=;R#2((8Q$TM_
MJ;1PQ6X^T3S-$-Q^^?%:K_PHW7Y!NX^%NK!6#87S'\+7"A2 ?X7SR21M   K
M\POV1O@'\*?$/["OB?Q5XC\%>'M>\1:_I'Q/U.[UG7M)T_4-0@FT^76(M.33
MKZZMI[NTMK!=.M)+6*"6%8YXC(-IP::BIIW=EK'5/5MI6T=VK[O:*;NM=?VW
M,*7$609[PM0X8Q4*F'GPSCLZS7#9YG.+S?GC0PV55HU\%&4.6EB*F(P]>G[2
M51WI)P5.TDY?K._CSP7#X2/CIO%.B1^#AI[:R?$4VHVAT5].53(;M+Y2\4L!
M&"AB)=I-H3#$ ^$_#']LK]FKXM^)W\'^"/BAHEYXD65H[*QU!;G1VU:5)&C,
M&D'4ULQJ\Q +QQ:?Y\ODD2F,J-U?B3J>N>,-:_8"_9F\.NXU?P_XC^*D^DZO
M%K.M7FG6%]!;:K>IH7A_4M36Z M=$NI9-MS$ZO&8[-8P%W**]6_:"\ ?&"'P
MI\/=2\0_";]FCX"/X:\8^%;CPEX]T+XAVUGJ'VL3)"FGVRCP^EE.;VU3S5CU
M*/6(V;Y1$) 9ZM8*E)2;DHV2=E=K6RUE'2+=VKR6NV^IQ1\;,[Q=6ABLORC#
MOZG@<JQF9O&R5*I76>5<5AY4:'/.DXTH?4_W/+&3?.XR2;U_7_XH_M5_ /X)
MZEJ.B_$3Q[IGA_5=/TJSUR;3+A)I[J;3K^XEM;-K...%VN+F2>)U\B!I)"J,
MVQ0"RM\6?M6? 'P?\//"_P 3O$'Q%T*T\)^,;2VU3PK.)GEO_$L,WEE5T?2H
MC/J5VUOYB?:X;>WD\ELI<M$P-? 7B/P/X=^(7_!2#X;Z?XYTS1_$MCI_P'_M
M2>VU&SM=3TZ]U58[\I?20W,<UO.MNTDK664>(+(6*X*JN9^T-;_#ZW_:L\'>
M!OA+\ 1\8/BK\/OA[IUA!X6\0ZU9Z!\&/AYX)O[FWNG^SZ.-(N+=+]EU>RNG
MN'2]MH]RPVEE T1(7U:"FHIMRNTFKNZ5MTMW9Z16JZZ'KUO$3BJCEN>9Q&GP
MW@<#@\YP609/1J?6*N)I8K'5Z%.5>4*<*LJLZ,:E6\8Q<7.$FIVLY?I'\'?V
ME_@M\>8-2;X:^.--\0W&D/(VJ:9-;W6FZG;0P)&\MXVC:E%;7WD8E3$PA:,$
MD$A@5'G&O_M\?LI>&'G34_BUHD=W:ZQJ.A7-A;PW-[=VM_I4S6M^+NULK>>:
M&SMI5:,W;JL!=65)6"8K\YO@?!XRTO\ X*%1V_C?P5X ^'>K2_!_Q*9?"7PM
MNHY="MM+DL+QX)M0N;6QTVVN=3FO&GF8"PMGCB^S!U=D1SZ!_P $[OAE\)O%
MFB?M#ZSXI\->&]>U^X^*?BS1M0&M6FG:E-!X=AU'4)8(H[>ZB$EE"SRRR3,C
M!;F0EQ*"I"R\-%-WLK.UO/JFD[]K[<J>[U/.RKQ2XJSN>3Y7@<+P_@,3B,[X
MPRRKB\QG*E"MA.'O9UL#CL,IR@U5Q4'6DJ4Y*<8Q?/3C*RE^M&@^/_!WB'PK
M;^-]'\0Z3>^$[NP;5(/$,=_;RZ4EFA_?79O2_P!G6*W0LT@DD4QE&#JI5MO@
M/AO]MW]F3Q5X\;X=Z)\5-!N?$AOYK" LUQ::5J5];R)&UGIVM2LNE7UQ,TB+
M#;VEQ,\^"$1B5 _$F?Q'XJ\(?L8?M*^%_ 5Q<1>!X?VE)/!\T<#7CV/ASP'<
MKJ.H7ZV%U&56SLY=7L]/L;J:V9D1;Q[/:SR 'U_XG?#/XE3_ +/ATV_^!'[,
MW@#P9IOA[1)=#^*,/Q,TVWU72(]/@M?[%UQ]5E\,6\M_?3ND<]P%O,3O,P+R
MLA9Z^IQES2]UV@I:7E97<;.2MRJZO>5TKI)7>I/QEXAQ53 8;+\!@W7A@8XO
M-,1B+*&-<,;C<'4AA)<T(1H26#YJ<KR?--QLWRM_N'K'Q8^'_A_QIX8^'NJ>
M);.T\7^-(;RZ\/:,T,OGZC!:#=<2JZ';:K;JP#%BC/@LNYBP$'B3XM_#KPGX
MV\._#?7=>MM.\9^+-,O]9\/Z-+#.?[2L=,BNY[MDEA/V8&%;"X++*0Q,?R<E
M6K\JVO=>3]H_]A.]\:ZKH^H:Q+\,]:BU#6]*N(I]$U&^%H%CGTC4.%O!=VRP
M3*4;:S,Y10N!7I?[05]IE]_P4-_95M[>X@NIK3P;XL2ZB4I(]B\]IXG:WCF!
M5C ]RDN8DE %Q"CA!DY.7U2'.K6:<UJ^5JSY7JUWYGI?6VSU/H(^*>*EE6+Q
MCP.6X;$X3.\CR[#T95(^WC2SO$4*52K&ES<TY4/;N4>2+3<5JU>W6? ;]N+P
M_P#%+]H+XJ?#G4O$_AE="BU.PT#X2Z?907#7?B4:?!?-K^I3W<B31"Y1Q%92
M0R(B(BQ^659Y0?6?V4?'NK:OX)^)>O\ CWXM^%OB%;Z%\4/&,,.L:,'L;+PM
MHVF7]Y##X?UBZODMO,N; 1@RS2I' L92.%B@0'YH_9(\$^"X_P!JG]K\IX<\
M-V]QX9\8^'?^$69=$TN*?0H[S2;^74/["FCMVGLDNKEC+?BV>"26:6)IS*(X
M5B^&O[6U_2OV,_VG+/18Y5TKQ#^U9J.A>,[J 7$<]EX6N_$]FVHS_:9'>38Z
MQ:;;K<-(4D%W+;(L8RM=$L/3:7*X7BY-M:744]+V]5IK%.[UU?R&7<<9]E6&
MP&:9GB89OC85>+EET:%6FHTJU!+#K#8J+J)1A2EC*-Y3BE%6<973DOV;\)_M
MM_LR>,O'*_#O0/BIH%SXH>Y>P@#L]II=[>6SF%K?3->GCBTS4Y_,E$8AM[HL
M68"/<&RW4?&3]J_X"_ B\L].^)?CZRT75KR(3P:=#!=ZMJHMW;RUNI],TR"[
MNK6TW JEQ<QPQ/@E6.,U\R?$;X$_L9VG[/\ X&F\<MI'P_\ !VCKX)ET/XC>
M&1;Z)XFEU.5;=]'N7\2Z+HLUW+_;4PBDNIUCC2]? =HDD8'YA^(_@/Q;-^T3
MXS^)W[//_"F/V@MOAOPM9>.OA_XU:WOO%.A6MIHUK'9+IMYJ"-)!>Z]!:VMW
M]HMG=)B##=6T;['?-86$I<K5GS)62;=FF[J*]Z:M:UGJKO5GTN;<?\89/E&%
MK1APWCZ^+I9=BJ<\!6C.IAL++ 48XFGB,)*:KU:]+&*O%NC&?M(13@IW3?[&
M_#7XG^!OBOX<L_%W@#Q1H_BOP]?LZ1:CHUY'>PQRHHDDMKL1$O8WD*L/-L[E
M8IH2=I4' KT?<.Q..V,X_#YZ_+3_ ()R>)/ ,R_&;P=HWPSUSX2?$32_&<?B
M'XE>#M6UDZQ8)JVIVTZPW'A]H[:U@LM)M9X[FP&FA&EA:-'>>X1E<?J.I#*&
M'1@"/H1GOS7#5AR3DM-W;WO-KLWI;9I,_5."\[EQ-P]@,XJN$JF)I1]JZ<:E
M*DJ\4U6C"%6G3J149JR4J<7ONDF_AK_@HOX(;Q]^QM\;M(CEE2;1O#5MXSMT
MMHC--=7'@G5-/\6I:)$OS-]MDT<6AV@[%G+X.P"OX^;&\:RN],U8>8/L-W8W
MH-L9%NE%IJ,-T#!NP4D>"T=RP&8P0.^3_>1XJT:R\2>'=;T&_0&QUS2-0TBZ
M^56/V?4+9[20QH58&14E)B!0KYNP$;>1_#M\7_A_J'PD^*OQ#^&>KQM#-X,\
M5:IHR>9*\RW&CM?1OHLT5Q(J&0WNC7D-XQ"_*SN@8XVC^\_H69YA\3@^/> \
M5*$JV9PEC,%"=2$(SIXZE/ XJE&FU><J-.<Z\FI>_"#@E%RYU_)_TJ<FK9?F
M_"7%\(R]GAX1RZLH0DW">%FL32KNLKP4:DH0HJ#AS1G-3<FERO\ 1;]OFQAU
MGQA\*_C#I%M;'0/BM\)_#=U;7D:E[K^U-,3R;P7\Z[H&G$<MM&K[MZ[?GPY<
M#X+C(VLS+DIQ@?+SDCJ.HSU[ #N>1]Z?!ZXB_:7_ &*?$GPK0PWGQ3_9JU:?
MQ%X7MG:0S:EX(F"37\5M'$&N+IK:*::,H8VC$\,(4LX 'P2Q$8;S"(=IVOYK
M"+82NTJ1(5&X'[PSN'0C/%?R=QSPIF'#/''$'#D\/5JUL#G>+I8>G3IS56O@
M56=2A.A1=Y554C4:Y8WY6KW::9_'OC/EDJ6>99Q127+EG$&587$NI1@ZBEF?
M+".)PLW!I*JN:GJUJIKW3 U36+BQNX[."U%Q(T/G#(+"0C)=5 96R@[+GD\G
MUKV^I>)=2P--\-ZA=L0&6.STO5[N:0MQL5(K*X7*XQE9&+9Y .<>P?#GXFZW
M\+/$3>)_"Y\.2ZJ;&?3\Z_HVBZ_:)#=;=\@MM5M[N.-U /[R)%<Y(+<U]"VW
M[=_Q[LMK66H_#/37&X(]M\/?!]G+M'"C>FDGH,Y;(QSQUK]0X?XFX1R? 8;"
M9AX/8C.,WHQG]9QN8U\;@:];FDY4N?#0J0C"$*3C"G)13J4[5'=N[\CA_#^'
M^)R[FS_-,RP>/HJ;K82A1FDFYMP49Z)2]G9R]WXNR/BN;PS\3[JVF2Y^%7B^
M\M9HSY8;P3XG/D,P!#02+IG[MCP2R$ DDYYYZWPA^SI^TMXBM)[_ ,(?!?XF
M7R*G[^XB\+:G:*S#D!TO8$1AM^43>4CCDDE<K7T?KW[>W[2FMON?XPWFD>5A
M1%H%CHFE1 @;0%BM=/9648PH XX(]!Y]J?[9WQ\U2&73M2^-WC[5+65BMW8V
MUY%"UQ%C][$'M([&4*ZX5F5V*J<JH."/U3)?%3C7%9-A^%.&O!+*<-ETZ\84
ML-F.&S_%82TJL9RE5IXZDJ$H*$747-4A#FC&:E=0YOJZ4O#"A1=*%+CW%T8Q
M<HJEE\**7*G)KG^M8AI-*W,J4FXOX5S7CU_AO_@GA^U!K\-CJ'C0>&?A=HVJ
M R/JOCWQ/IUFU@<*QMY=/6[@OFF>+>5B**D@!.XA&*^R^)K/]GS]F'X$?$;X
M->!?'-K\:/BU\7GTVV\8^)M'\NW\/^$[/0YX[@:?92QM/%=-!-%,PC$PF='4
M,%.T-\L_LRZ-\1OVAOCIH7P^%[XD\5>&M7>\'BVSU;6-0UNT\)>'[VXMTN-9
MGFNYKJ'3KJS6-I]"D6[2YNM0\ZW9!$&-<1XBT0^&M?\ $7AI[F.\G\.:]J6A
MSWL/_'M>G3Y)8&O(^Y%V\3-&Q&_:X#$=3\#X[<0<<91]2X-Q^99#E^ QF%PN
M;5LCX9PBP5+!.<HOV&*C]8KN;2]R+O"/M(RDZ7+:*^AS;B'+^$N&:&.X2X,>
M#7$."QN6X;/\]I*6(ITZ^'C',(PPSI0E+$_5ZJE2KII4I24DF]3%!VX P ./
MFYQQWYQQP/RY[!^]A_$HSS]T?GUIB8#') QQT Z'MU_'(_/&*>()KJ18+2.2
M>XG>VMH;> ,)9;FYNXK6R0$!V(EN)PB*B%Y&)R"J\?S7*\YR<'5J.3NO:24Y
MJZ6G-&*7*NEEHF?S?0I2G4P6#HRQ6*J8N<\-@75?MJ]>K3G+GIR<(KEC3J57
M&#DG[K7\MS]?O^"0G@*34/B#\4/B)>6MG)8:#H^C>'M*NY7S/#J>L7=[<WJV
MZ>6/)5[6P*7#*Q#N0[9/-?L+^T'^SUX3_:+\+Z5X4\6ZKK&DZ?I7B'3O$-O+
MHLD$=P]YIBR[(Y)+F.17M9 ^75%64%597"[U;S+]B'X%/\!O@-X3T+5(47Q=
MXCA@\4^*P=S,FK:Q;Q3'36=E1RVD6@M;%P4\OS8;ITSYK%OLIR!M#%5+.L:#
M<JDNV<*O()8X/ Z ,<  D>77G+VBC[BE!OFC[1.2LW=\JBF];::6U5]#_8[P
M;X#HY!X4</9!G6%HU7F&#6-Q^'E&T:U3%0H8JG&I&][TE4I1ES2;<J+:<;J,
M>2O/"]A?^#[OP;/+.VF7NAW'A^XNED2&Y6VN;"2P,T,I#PFX6"0ODIY?F=L
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M(%CX1C>.5F<2".&5 1&)  QR@3[XX[]O7X"_M-?%_P#:F\+^+Y/C'^S?X?\
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MO.GD?>&('# 5X'^T+^SQ^W5X.\)^-_VM/$>D_!WXE7/Q,_9)?]EZ[T'X8?\
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MR^3$P+, ??2%BHW#!'!]\#K^-.IJ,64$@@X&<C'.!GCG'.1CJ,4Z@"*3JI[
M$$]ADKC-0G!(;Y3MZ'@D;C@X/;H,XZCKVQ;(!&" 1Z'D4W8O]U?^^11W\TUI
MYIKR[B=]+=&G]S3M\[6/!_CQ\"OA_P#M"^ ]3^'GQ$T>'4M&OE#V\Z+MU/1M
M2C*?8]6T:Z09MKJUE^=TR4EC#+*K1.5/\J'[6?[#'Q5_96UM[R_LIO%OPWU*
M;4KC2O'&EQ2W$-O  I>'Q#;PPL-)N#"^&,[+%*BR9++E:_LD\I222JCZ >P[
MCT_6N=UGP[I?B+3;G1]9TS3M6TJ_M9K.[TW4X!=6-U;SHR21SVTBO#(KH3N6
M2-P>G!.1^Q>$GC7Q7X39C">7598W)J]2G_:&5RJ2]G4A!R?-04Y.&'JM5)JI
M*%-1JVC[1.2C-?DOB=X1Y!XD8"NJD(X#/%!O YG.G&4*4WR\RKJ,)2JQER0]
MFY\[I^\XN*;3_AH^&'Q5^(7P<\11>,/A5XJO?"OB"(*IN-,F1+?4X,>6UIJ5
MLRR65_8/'D3B=&E2-8X[9T9FK]&M/_X*!_"SXKV=OHO[6GP#TCQ?.EK/9R?$
M'P):QZ-XC6)[2&(7;V7VCS?MLEPA=$>3%LJL41 2#]^_M'_\$@/AEX]O-1\1
M_!36S\+?$%S.UY-X>DM&U7P1=3A_,=8].40W&E),, 16,JPK( Q0C('XZ?%?
M]@3]K#X1O=3:Q\*-9\5Z19C/]N_#R.3Q=:7&Z;RH?*TNPC;7H)'4J\D#Z:T=
MN-R"XF(WU_:-+BOZ./CK1HO.Z.!X<XB:E*I1K5J?#N/JUF_>4L^]E.CB>=WG
M3C)2]E%J*YFKG\;YMP;XM^&]6IA9X?$<0\/4+*IA\PP=/B#)L53:4G+!93R2
MJ85ZI5I>WHN=6\URW2/K*Q^'_P#P3B^(]Y&/"OQ[\:_#:_O[2&>WT/Q1I^_3
MM)F0[=MU?W.EHK.3\[*]^$(8L'P!5Z+]CK]G%IA,?VU_AN]DSE]L7V%YS;]7
M!<7959MAX7;PQ&!7Y#ZOHFLZ!>R:3X@T#6-"U.TS%-IVM:'?Z5J%K*V&4RV5
M_#:71."#L>/Y0<$'D5C@VX<9BBN"<# 6)68GL%$D\@8$9*B%3@<DC@^3B?HC
M< XZ4,1D_B56P>$J.3]G4QF35+IJ4N6-6>+@Y))\JE+E4U%3NN>Q\34SCAF=
M1?VKX-93*JV]:='.:*<M7?V=/#24$Y:\EVHJT$[1N_UYNO#G_!-/X=SZI)KO
MQ@^('Q5O-'C%NVA>'K&XM[?4KL.I:73[RW@2.:(892!<956!8\"N9\0?\%#O
M"WPYT^]\-_LG?!#PY\-H)E%F/'7B2UBUGQ3/%Y81;U+=K@L)[G")/!<R-'$^
M^=E4]/S*T/P[XC\4WZZ5X6\-:_XDU>5#)%I'AO1-2US43$#C<MGIM@9CMR1_
MJRQ)^\V0!]F_"3_@G9^UC\7)+&X7X>7OP_T&Z6.1==\?(^@RB R!)WBT.<)K
MOVF)2TBPW5C:1S$%5N%&37;@_!#Z/7A[3IYCQAQ;2SBIAY3E[/&YI@?90J4D
MJEX4,)7Q$Z\J_+[/D]G65KVBDW;W<LS/BK&5%@^!_#G*N'_:\L'7PV7XNI7G
M3D^6FI5L3A%4I*G-NHI0K4FY2UE9)'R)XW^(/C3XC>(;WQ7\0?$^J^*?$5[C
M[5JFKW8NI4&R95AA.(X[>'R7E2*VL(A:>0&CD9G$>[[=_8__ .">_P 4/VF+
M^T\2ZW#=>!?A);WD$.J>(;^WDAU;7[-(X+F:T\+6%Q#OG@EB:"VEU8?NH%D=
M(6#P.*_7;]FO_@DS\'_A3<Z?XI^*&H'XN^,+5K>XBANK-;'P9IES 5)6TT &
M9-1V,"JW-^ZN09%:-2Q-?K#IFE6VGVJ:?86MI86-K%%#:6EI EM!# B[8X8X
M(8HXH85"E5AB!51T;DU^?^)GTK<LP^2U^$?"+):>685Q>#Q.<UZ,*2HX>G>G
M"KD,(T</46)G3@I5:U6G2BZGL^7GMS+]Q\/OHYYCC<PAQ)XD8R->I:4X952G
M5<I0;34)2E4G:-12ESTW)Q=K.%FSA_A3\+/!GP?\$:#X \!:);Z%X:\/V,%G
M:6<"[GE=(X1)>7=PV6O+J[:/S;RY<N\DTDDA;)..[U/3K#5-.O=+U"TM[O3M
M3M9].O[.93Y%U87D;VUU;2A,-Y<D$D@.P@CDJ>M::0NJ@$IP ,#.T8&  #T
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M&BBL:$I2A+F;?+4J15W=J,96BKOHEHAPE*:O)MN[5WV6R^5V+1116Q04444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
